GYRA, GYRB: DNA gyrase
Complex in Neisseria gonorrhoeae that 2 drugs act on.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on GYRA, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
| Enoxacin | Approved | Sanofi | Small molecule | InhibitorDNA gyrase inhibitor | 0 |
| Zoliflodacin | Phase 3 | Entasis Therapeutics | Small molecule | InhibitorDNA gyrase inhibitor | 2 |
| Pharmacokinetics of Oral Zoliflodacin 3 g in Healthy Lactating Women | Zoliflodacin | Phase 4 | Not yet recruiting | Global Antibiotics Research and Development Partnership | Nov 9, 2026 |
| Study to Evaluate the Effect of Zoliflodacin on Testicular Function in Healthy Adult Men | Zoliflodacin | Phase 4 | Not yet recruiting | Global Antibiotics Research and Development Partnership | Jun 10, 2026 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2311244, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets